Useful Information
Educational guides and research data for GLP-1 receptor agonist studies
What to Expect: Research Timeline
Based on published research data, here is a general timeline of observations reported in GLP-1 receptor agonist studies:
Weeks 1–2
Possibly nothing at all — or you may notice a slight decrease in appetite or mild nausea as your body adjusts. Some people feel changes early, while others take longer.
Weeks 3–6
Appetite suppression becomes more noticeable, and you may start seeing gradual weight loss. Blood sugar levels begin to stabilize.
Months 2–3
Still adjustment months. Your dose is increasing slowly. Many people experience: steady weight loss, reduced cravings, more energy, and better digestion.
5+ Months
This is when real transformation happens. Consistent weight loss, appetite regulation, and metabolic improvements. Habit changes start to take root.
Foods to Avoid on GLP-1
These guidelines are based on research into digestive tolerance during GLP-1 receptor agonist administration:
⚠️ Avoid / Limit
✅ Better Choices
General nutrition guidance — does not replace advice from a healthcare professional
About Our Research Compounds
Tirzepatide (Mounjaro)
A dual GLP-1/GIP receptor agonist that has shown significant results in clinical research for weight management and glycaemic control. It works by mimicking the effects of two incretin hormones, leading to reduced appetite and improved metabolic markers.
Retatrutide
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Early research suggests it may offer enhanced efficacy compared to dual agonists, with studies reporting significant reductions in body weight.
GHK-Cu (Glow Skin Tone)
A naturally occurring copper peptide with research applications in skin regeneration, wound healing, and anti-ageing. Studies indicate it may promote collagen synthesis and improve skin elasticity.
